09/30/2008
Baxter's Antimicrobial IV Technology Now Shown To Kill Six Common Pathogens, Including MRSA And VRE (Medical News Today)
Baxter Healthcare Corporation announced that it received 510(k) clearance for expanded labeling for the first antimicrobial needleless intravenous (IV) connector, V-Link Luer-activated device (LAD) with VitalShield protective coating.
MORE INFO
|
09/29/2008
Baxter's Antimicrobial IV Technology Now Shown to Kill Six Common Pathogens, Including MRSA and VRE (PR Newswire via Yahoo! Finance)
Baxter Healthcare Corporation today announced that it received 510 clearance for expanded labeling for the first antimicrobial needleless intravenous connector, V-Link Luer-activated device with VitalShield protective coating.
MORE INFO
|
09/26/2008
Sum to be spent over five years (The Jamaica Observer)
The government will be spending $2.1 billion over the next five years to assist sugar-producing communities to survive the divestment of its sugar factories.
MORE INFO
|
09/24/2008
Gerlach accepts Golden Leaf presidency (Triangle Business Journal)
Dan Gerlach, lead economic adviser to Gov. Mike Easley, has formally accepted the presidency of the Golden Leaf Foundation.
MORE INFO
|
09/22/2008
Myriad Genetics Announces Topline Results Of Phase 1 Trial Of Vivecon For HIV (Medical News Today)
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that it has successfully completed dose escalation in the Phase 1 human clinical trial of Vivecon(TM), its HIV viral maturation inhibitor, in healthy volunteers. The trial demonstrated a favorable safety profile with Vivecon in 55 subjects enrolled across 9 cohorts.
MORE INFO
|
09/21/2008
LOCAL BRIEFS (Asbury Park Press)
Fred Fastiggi of Brielle has joined Birdsall Services Group, Sea Girt, as vice president of energy services. He will lead BSG-PMK Group in providing energy and sustainable development services.
MORE INFO
|
09/19/2008
Trial Indicates Favorable Safety And Pharmacokinetics Profiles (BioresearchOnline)
Myriad Genetics, Inc. announced recently that it has successfully completed dose escalation in the Phase 1 human clinical trial of Vivecon, its HIV viral maturation inhibitor, in healthy volunteers.
MORE INFO
|
09/17/2008
Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV (Marketwire via Yahoo! Finance)
Myriad Genetics, Inc. (www.myriad.com) announced today that it has successfully completed dose escalation in the Phase 1 human clinical trial of Vivecon(TM), its HIV viral maturation inhibitor, in healthy volunteers.
MORE INFO
|